141 related articles for article (PubMed ID: 38503890)
1. Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy.
Pang J; Ding N; Yin N; Xiao Z
Sci Rep; 2024 Mar; 14(1):6578. PubMed ID: 38503890
[TBL] [Abstract][Full Text] [Related]
2. Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy.
Ding N; Huang J; Li N; Yuan J; Wang S; Xiao Z
BMC Cancer; 2020 Mar; 20(1):235. PubMed ID: 32192443
[TBL] [Abstract][Full Text] [Related]
3. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
[TBL] [Abstract][Full Text] [Related]
4. High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab.
Jiang L; Fang J; Ding J
Cancer Manag Res; 2020; 12():475-484. PubMed ID: 32021460
[TBL] [Abstract][Full Text] [Related]
5. [Effects of adjuvant trastuzumab on long-term survival of T1N0M0 stage human epidermal growth factor receptor 2 positive breast cancer: a real-world study].
Sun TH; Lu ZN; Song HT; Sun G
Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):101-107. PubMed ID: 36709127
[No Abstract] [Full Text] [Related]
6. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
7. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
Gori S; Inno A; Fiorio E; Foglietta J; Ferro A; Gulisano M; Pinotti G; Gubiotti M; Cavazzini MG; Turazza M; Duranti S; De Simone V; Iezzi L; Bisagni G; Spazzapan S; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Santini D; Fabi A; Garrone O; Frassoldati A; Amaducci L; Saracchini S; Evangelisti L; Barni S; Gamucci T; Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L
PLoS One; 2015; 10(9):e0136731. PubMed ID: 26340098
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
9. Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.
Hamy AS; Belin L; Bonsang-Kitzis H; Paquet C; Pierga JY; Lerebours F; Cottu P; Rouzier R; Savignoni A; Lae M; Reyal F
Br J Cancer; 2016 Jan; 114(1):44-52. PubMed ID: 26657653
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of prognostic nutritional index and systemic immune-inflammation index in patients after curative breast cancer resection: a retrospective cohort study.
Xu T; Zhang SM; Wu HM; Wen XM; Qiu DQ; Yang YY; Wang LZ; Zhu WB; He LS; Li JJ
BMC Cancer; 2022 Nov; 22(1):1128. PubMed ID: 36329394
[TBL] [Abstract][Full Text] [Related]
11. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
12. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
Pang J; Wang S; Liao L; Liu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
[TBL] [Abstract][Full Text] [Related]
13. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
Hayashi N; Niikura N; Yamauchi H; Nakamura S; Ueno NT
Breast Cancer Res Treat; 2013 Jan; 137(2):523-31. PubMed ID: 23184079
[TBL] [Abstract][Full Text] [Related]
14. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment.
Kubota K; Ito R; Narita N; Tanaka Y; Furudate K; Akiyama N; Chih CH; Komatsu S; Kobayashi W
BMC Cancer; 2022 Apr; 22(1):368. PubMed ID: 35392843
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
[No Abstract] [Full Text] [Related]
16. HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab.
Li S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
Breast; 2020 Dec; 54():235-241. PubMed ID: 33166784
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
[TBL] [Abstract][Full Text] [Related]
18. Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
Fujita N; Fujita K; Kim SJ; Iguchi C; Nomura T; Aono T; Yanagisawa T; Enomoto Y; Inakami K; Miyagawa Y; Tomoike R; Kasugai T; Shiba E
Oncology; 2022; 100(5):257-266. PubMed ID: 35114682
[TBL] [Abstract][Full Text] [Related]
19. Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients.
Furrer D; Jacob S; Michaud A; Provencher L; Lemieux J; Diorio C
Clin Breast Cancer; 2018 Aug; 18(4):e687-e694. PubMed ID: 29275864
[TBL] [Abstract][Full Text] [Related]
20. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
